Indications for Avatrombopag

Avatrombopag (Avatrombopag) is an orally bioavailable small molecule thrombopoietin (TPO) receptor agonist that does not compete with thrombopoietin in bindingTPO receptors and has additive pharmacological effects with TPO on platelet production. Avatrombopag is indicated for the treatment of thrombocytopenia in patients with chronic liver disease who are scheduled to undergo surgery and for the treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP; also known as idiopathic thrombocytopenic purpura) who have had an inadequate response to prior treatment (designated as an orphan drug by the FDA for this condition). Follow recommended dosing guidelines to achieve target platelet counts to minimize bleeding risk; do not use to normalize platelet counts.